Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron

Olha Puhach[1], Kenneth Adea[1], Nicolas Hulo[2], Pascale Sattonnet[1], Camille Genecand[3], Anne Iten[4], Frédérique Jacquérioz Bausch[5,6,7], Laurent Kaiser[5,8,9], Pauline Vetter[5,8,9,*,#], Isabella Eckerle[1,5,9,*,#], Benjamin Meyer[10,*,#]

Affiliations:

[1] Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland

[2] Service for Biomathematical and Biostatistical Analyses, Institute of Genetics and Genomics, University of Geneva, Geneva, Switzerland

[3] Cantonal Health Service, General Directorate for Health, Geneva, Switzerland

[4] Service of Prevention and Infection Control, Directorate of Medicine and Quality, University Hospital Geneva, HUG, Geneva, Switzerland

[5] Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland

[6]Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland

[7] Primary Care Division, Geneva University Hospitals, Geneva, Switzerland

[8] Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals & Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland

[9] Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland

[10] Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Switzerland

[#] *Corresponding authors*

Benjamin Meyer: Benjamin.Meyer@unige.ch

Isabella Eckerle: Isabella.Eckerle@hcuge.ch

Pauline Vetter: Pauline.Vetter@hcuge.ch

* Equally contributed

Abstract

Background

Viral load (VL) is one determinant of secondary transmission of SARS-CoV-2. Emergence of variants of concerns (VOC) Alpha and Delta was ascribed, at least partly, to higher VL. Furthermore, with parts of the population vaccinated, knowledge on VL in vaccine breakthrough infections is crucial. As RNA VL is only a weak proxy for infectiousness, studies on infectious virus presence by cell culture isolation are of importance.

Methods

We assessed nasopharyngeal swabs of COVID-19 patients for quantitative infectious viral titres (IVT) by focus-forming assay and compared to overall virus isolation success and RNA genome copies. We assessed infectious viral titres during the first 5 symptomatic days in a total of 384 patients: unvaccinated individuals infected with pre-VOC SARS-CoV-2 (n= 118) or Delta (n= 127) and vaccine breakthrough infections with Delta (n= 121) or Omicron (n=18).

Findings

Correlation between RNA copy number and IVT was low for all groups. No correlation between IVTs and age or sex was seen. We observed higher RNA genome copies in pre-VOC SARS-CoV-2 compared to Delta, but significantly higher IVTs in Delta infected individuals. In vaccinated vs. unvaccinated Delta infected individuals, RNA genome copies were comparable but vaccinated individuals have significantly lower IVTs, and cleared virus faster. Vaccinated individuals with Omicron infection had comparable IVTs to Delta breakthrough infections.

Interpretation

Quantitative IVTs can give detailed insights into virus shedding kinetics. Vaccination was associated with lower infectious titres and faster clearance for Delta, showing that vaccination would also lower transmission risk. Omicron vaccine breakthrough infections did not show elevated IVTs compared to Delta, suggesting that other mechanisms than increase VL contribute to the high infectiousness of Omicron.

Funding

This work was supported by the Swiss National Science Foundation 196644, 196383, NRP (National Research Program) 78 Covid-19 Grant 198412, the Fondation Ancrage Bienfaisance du Groupe Pictet and the Fondation Privée des Hôpitaux Universitaires de Genève.

Introduction

As of 2 January 2021, the coronavirus disease 2019 (COVID-19) pandemic led to a total of nearly 289 million cases and just over 5.4 million deaths globally (1). Severe acute respiratory coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, primarily infects the cells of the upper respiratory tract (URT) where it leads to an increasing viral load (VL) during the course of infection(2).
The two key parameters when assessing VL are either RNA genome copies, often expressed in cycle threshold (Ct) values, or infectious virus that can only be assessed by virus isolation in cell culture. Although the process of human-to-human transmission is complex, VL can serve as a proxy, with higher VL posing a greater risk for onward transmission. In several epidemiological studies, higher viral load expressed as viral RNA was associated with an increased secondary transmission in household settings(3, 4). Shedding of infectious SARS-CoV-2 in the URT starts on average two days prior to the beginning of symptoms and gradually declines up to 8 days post onset of symptoms. Even though viral RNA could be detected afterwards, in most studies infectious virus was not detected in respiratory samples collected from immunocompetent individuals later than 8 days post onset of symptoms (5-9). Moreover, the detection of viral RNA does not correlate with infectiousness in an animal model (10). Instead, success of virus isolation in cell culture was found to be a proxy for detection of infectious virus from respiratory specimens and the ability to shed and transmit fully competent viral particles (8, 11, 12). Virus isolation success can only give information about the presence or absence of infectious virus, but is not able to quantify the infectious viral titre in samples of the URT (13).
Since the start of the pandemic, SARS-CoV-2 is constantly evolving, leading to the emergence of new variants. While most variants vanished quickly, other such as D614G, and the designated variants of concern (VOCs) Alpha, Beta, Gamma, Delta and Omicron harbour an apparent selection advantage and manage to replace other existing variants locally or even globally. These VOCs exhibit various mutations and amino acid alterations in viral proteins (14) that lead to immune evasion and/or higher transmissibility to which increased virus shedding among other factors like environmental stability can significantly contribute (15, 16). For Alpha VOC, an approximately 10-fold higher RNA viral load was observed compared to pre-VOC viral strains, that was also associated with an increase in virus isolation success (17, 18). Similarly, Delta VOC also showed 10- to 15-fold higher viral load on RNA level compared to pre-VOC strains (18, 19). However, little is known about the quantity of emitted infectious viral particles for VOCs including Omicron.

There is extensive evidence that introduction of licensed vaccines against SARS-CoV-2, which were designed against the original virus strain, led to the reduction of cases and disease severity. However, the effect of vaccination on infectious viral shedding and onward transmission from vaccinated patients remains controversial. Considering that all currently approved vaccines are administered intramuscularly, the titre of neutralizing antibodies on the mucosal surfaces lining the URT might be limited, and therefore sterilizing immunity is probably only transient if achieved at all (20, 21). Epidemiological studies on the secondary attack rate in households of vaccinated vs unvaccinated index patients led to contrary results. While some studies show a reduction of transmission rates in vaccinated index cases (22-24), one study found no influence of the vaccination status of index cases (25). However, many additional factors, such as the behaviour of index patients, age, comorbidities, the variant present at the time of study, time elapsed after complete vaccination and the vaccine used, can influence the secondary attack rate in these studies. Therefore, it is difficult to delineate the effect of vaccination on viral load from other factors in purely epidemiological studies. An overall reduction

of RNA viral loads was reported in vaccinated COVID-19 patients (BNT162b2 mRNA vaccine or ChAdOx1 nCoV-19 (AZD1222) adenoviral vector vaccine), but no difference was observed at 6 months post vaccination (26, 27). Another study found reduced RNA viral load early after complete vaccination when the Alpha VOC was prevalent, but no difference at later time points when the Delta VOC was dominant (28). In addition, a study that investigated the kinetics of RNA viral load in COVID-19 patients did not find a difference during the first 5 days post symptom onset, i.e. when most human-to-human transmissions occur, but showed a faster decline of RNA viral load in vaccinated patients (29). Similarly, a lower probability of virus isolation success was found in vaccinated vs unvaccinated COVID-19 patients at the same RNA viral load indicating that vaccines can reduce the infectious viral load (30). However, no study quantified infectious virus titres of different VOCs in URT samples of vaccinated and unvaccinated COVID-19 patients.

Dynamics of infectious viral shedding in vaccinated and unvaccinated patients infected with relevant SARS-CoV-2 variants of concern requires detailed investigation. Understanding of the SARS-CoV-2 viral shedding in patients would help the implication of public health decisions to limit the transmission of the virus in the community (31). Here we compare RNA and infectious viral load between pre-VOC strains and Delta VOC in unvaccinated patients as well as in vaccination breakthrough infections due to Delta and Omicron. Respiratory samples from mildly symptomatic patients of different age and sex, sampled in the first five days post onset of symptoms were used for this study. By quantifying infectious viral titres from URT specimens, we show that patients infected with SARS-CoV-2 Delta variant of concern harbour elevated levels of infectious viral titres, while vaccination leads to a reduction of infectious virus.

Methods

Participants

Sample collection and setting

Nasopharyngeal swabs for diagnostics of SARS-CoV-2 by RT-PCR collected from symptomatic individuals in the outpatient testing center of the Geneva University Hospital were included in this study. Infection with SARS-CoV-2 was diagnosed by RT-PCR assay (Cobas 6800, Roche). All samples originate from the diagnostic unit of the virology laboratory of the hospital and were received for primary diagnosis of SARS-CoV-2. Remaining samples were stored at -80°C, usually on the same day or within 24h. All samples had only one freeze-thaw cycle for the purpose of this study. All specimens from vaccinated individuals were characterized by full genome sequencing for their infecting SARS-CoV-2 variant. Initial identification of the Omicron VOC was done by S gene target failure of the TaqPath COVID19 assay (Thermofisher) and confirmed by partial Sanger sequencing of the Spike (32). Final confirmation was done by next-generation sequencing. No sequence information was obtained for patients infected with pre-VOC SARS-CoV-2, as all samples were collected in 2020, in a time period before first detection of the VOCs in Switzerland. Clinical information of the patients was collected by a standardized questionnaire in our testing Centre and/or through the Cantonal Health Service.

Viral load quantification by qRT-PCR

143 Viral loads in each sample were determined by quantitative real time PCR (RT-qPCR) using
144 SuperScript™ III Platinum™ One-Step qRT-PCR Kit (Invitrogen). RT-PCR for SARS-CoV-2 E gene and
145 quantification of genome copy number was performed as described previously (33).

146 **Quantification of SARS-CoV-2 by focus-forming assay**.

147 Vero E6 and Vero E6-TMPRSS were cultured in complete DMEM GlutaMax I medium supplemented
148 with 10% fetal bovine serum, 1x Non-essential Amino Acids, and 1% antibiotics
149 (Penicillin/Streptomycin) (all reagents from Gibco, USA). Vero-TMPRSS were kindly received from
150 National Institute for Biological Standards and Controls (NIBSC, Cat. Nr. 100978).

151 Nasopharyngeal swab samples were serially diluted and applied on a monolayer of VeroE6 cells in
152 duplicates. Following 1 hour of incubation at 37°C, the virus-containing inoculum was removed and
153 the cells were overlaid with prewarmed medium mixed with 2·4% Avicel (DuPont) at a 1:1 ratio. Plates
154 were incubated at 37°C for 24 hours and then fixed using 6% paraformaldehyde for 1 hour at room
155 temperature. Cells were permeabilized with 0·1% Triton X-100 and blocked with 1% BSA (Sigma).
156 Plates were incubated with an anti-SARS-CoV monoclonal nucleocapsid protein primary antibody
157 targeting SARS-CoV-2 nucleocapsid protein (Geneva Antibody facility; JS02) for 1 hour at room
158 temperature and then with peroxidase-conjugated secondary antibody (Jackson ImmunoResearch,
159 #109-036-09) for 30 minutes at room temperature. Foci were visualized using True Blue HRP substrate
160 (Avantor) and imaged on an ELISPOT reader (CTL). Focus-forming assay for comparison of infectious
161 viral loads in Delta vs Omicron was performed in Vero E6-TMPRSS cells.

162 **Virus isolation**

163 Nasopharyngeal samples were applied on the monolayer of Vero E6 cells in 24 well plates. 100 µl of
164 each sample was added and inoculated for 1 hour at 37°C. Following the incubation, the infectious
165 supernatant was discarded and virus culture medium was added. 50 µL of the medium was collected
166 to define the viral load at day 0. 3 to 4 days post inoculation the medium was replaced with fresh one,
167 and 6 days post infection the infectious medium was collected to define the viral load at day 6. The
168 change of viral load for at least 1 log of SARS-CoV-2 genome copies from day 0 till day 6 was considered
169 as successful isolation.

170 **Statistical analysis**

171 All statistical analyses were performed using R Statistical Software version 4.1.1 (Foundation for
172 Statistical 185 Computing, Austria) and Prism version 8.0.1 (GraphPad, San Diego, CA, USA).

173 **Ethical approval**

174 The study was approved by the Cantonal ethics committee (CCER Nr. 2021-01488). All study
175 participants and/or their legal guardians provided informed consent.

176 Results

177 In this study, we analysed the viral load characteristics in the URT of unvaccinated pre-VOC- as well as
178 vaccinated and unvaccinated Delta VOC-infected COVID-19 subjects up to 5 days post onset of
179 symptoms (DPOS). We included a total of 384 samples in our cohort of which 118 originated from
180 patients infected with pre-VOC SARS-CoV-2 and 248 from patients infected with the Delta VOC. Of the
181 Delta VOC infected patients, 121 were vaccinated twice prior infection and 127 were unvaccinated. In

182 addition, we included 18 vaccinated individuals recently infected with Omicron. None of the patients
183 infected with pre-VOC SARS-CoV-2 were vaccinated due to the absence of licensed vaccines at the
184 time of infection. All patients had mild symptoms at the time of sampling. Samples of pre-VOC infected
185 patients were collected between April 7th and September 9th 2020, before circulation of any VOCs,
186 while samples of Delta VOC infected patients were collected from June 26th until December 4th 2021
187 and sample of Omicron VOC infected patients from 14th to 17th of December 2021. All vaccinated
188 patients included in this study were diagnosed positive at least 14 days after 2nd dose, which complies
189 with the definition of vaccination breakthrough given by the Centers for Disease Control and
190 Prevention (34). 132/139 patients were vaccinated with mRNA vaccines, one was vaccinated with a
191 non-replicating viral vector vaccine (CoviVac) and for six patients the vaccine used is not known. The
192 median time between 2nd dose and breakthrough infection was 79·5 (IQR 40·5-139 days) for Delta
193 infections and 136 (IQR 85-176) for Omicron infections. All three groups of patients (pre-VOC, Delta
194 VOC unvaccinated and Delta VOC vaccinated) had a similar age and sex distribution (see **Table 1).**

195 We quantified genome copies and infectious viral titres in SARS-CoV-2-positive nasopharyngeal swabs
196 using qRT-PCR and focus-forming assay. Only specimens with a CT values below 27 for the E gene
197 target of the diagnostic RT-PCR (Cobas, Roche), as determined by the clinical laboratory, were included
198 in our study, since previous studies from us and others have shown that in the pre-Omicron era
199 infectious virus cannot be reliably isolated from samples with higher CT values(12, 35). To validate our
200 focus forming assay, we compared it to the ability to successfully isolate virus in cell culture. Virus
201 isolation success has been used as a correlate of infectious viral shedding for SARS-CoV-2(6, 36-38),
202 but lacks the ability to differentiate between high and low viral load samples. We were able to quantify
203 viral titres using the focus forming assay in 91·9%, 91·7% and 83·8% of culture positive samples in the
204 Pre-VOC, Delta and Delta vaccinated group, respectively, indicating a high sensitivity for our assay
205 **(Figure 1A).** Overall, the Cohens kappa agreement was 0·69, 0·71 and 0·53 for the 3 groups, showing
206 a moderate to substantial agreement **(Figure 1 B).**

207 **Low correlation between genome copies and infectious viral titres**

208 First, we investigated whether RNA genome copies are a good proxy for infectious virus shedding. We
209 observed only a very low correlation (R^2 = 0·119, p=0·0001) between viral genome copies and
210 infectious virus particles for pre-VOC samples **(Figure 2 A),** while the samples from unvaccinated and
211 vaccinated Delta patients showed slightly higher, yet still low correlation (R^2 = 0·312, p <0·0001 and R^2
212 = 0·3962, p <0·0001, respectively) **(Figure 2B, C).**

213 **No correlation between infectious viral load and age and sex of patients**

214 Next, we tested if infectious viral loads from patient samples are associated with patient age and sex.
215 We did not observe any correlation between the age and infectious viral load for all three groups
216 **(Supplementary figure S1).** Similarly, no significant differences of infectious viral loads between male
217 and female patients were detected for pre-VOC or Delta variant samples from vaccinated or
218 unvaccinated patients **(Supplementary figure S2).**

219 **Delta VOC infected unvaccinated patient have higher infectious viral load**

220 Next, we compared genome copies and infectious viral loads in pre-VOC and Delta VOC samples from
221 unvaccinated patients during the first 5 symptomatic days. Overall, pre-VOC samples had significantly
222 higher genome copies (0·653 log, p<0·0001) compared to Delta VOC, but infectious viral titres were

223 significantly higher in Delta VOC infected individuals (0·343 log, p=0·0373) **(Figure 3A)**. When we
224 analysed the kinetics of viral shedding, we found that genome copies for pre-VOC samples were higher
225 at one and two dpos but similar to Delta VOC at 0, 3, 4, 5 dpos **(Figure 3B)**. Conversely, infectious virus
226 shedding was higher for Delta VOC at 3-5 dpos, but similar at 0-2 dpos **(Figure 3C)**. In addition, we
227 observed that genome copies remained largely stable until 5 dpos, with only a minimal decline at 5
228 dpos, while infectious viral load substantially declined **(Figure 3B and C).**

229 The association of the levels SARS-CoV-2 infectious shedding with patient age and sex is highly debated
230 (17). In this study we also did not detect a correlation between patients age or sex with their
231 infectiousness. However, there is increasing evidences of more severe outcomes of COVID-19 disease
232 in older male patients **(36, 38, 39).** Thus, to eliminate possible confounders, 84 Delta infected patients
233 were matched with pre-VOC infected patients in regard to sex, age and dpos. Similarly, significantly
234 higher infectious viral loads (0·51 log, p=0·001170) were detected in Delta variant samples in
235 comparison to matched pre-VOC samples **(Supplementary figure 3A).**

236 **Vaccinated patients have lower infectious viral load than unvaccinated patients**

237 To determine the influence of vaccination on virus shedding, we compared genome copies and
238 infectious viral loads in unvaccinated and vaccinated patients infected with the Delta VOC during the
239 first 5 dpos. Overall, genome copies did not significantly differ between vaccinated and unvaccinated
240 patients, while infectious viral load was significantly decreased in vaccinated patients (0·68 log,
241 ****p<0.0001) **(Figure 4A)**. The kinetics of RNA genome copies were largely similar between vaccinated
242 and unvaccinated patients with a slight trend of faster decline for vaccinated patients starting at 4
243 dpos **(Figure 4B)**. In contrast, infectious viral titres were substantially lower in vaccinated patients at
244 all dpos with the biggest effect observed at 3-5 dpos **(Figure 4C)**. Still, at 5 dpos we were able to detect
245 infectious virus in 7/13 (53·8%) vaccinated and 11/13 (84·6%) unvaccinated patients. Additionally, 67
246 Delta VOC infected patients were matched with Delta VOC vaccination breakthrough patients in
247 regard to age, sex and dpos. Infectious viral titres were elevated in unvaccinated patients in
248 comparison to vaccine breakthroughs (0·97 log, p<0·0001) **(Supplementary figure 3B)** confirming a
249 significant reduction of infectious viral titres among vaccinated patients. We further analysed if there
250 is a correlation between infectious viral titres and the time interval since the administration of the last
251 vaccine dose. We observed a high heterogeneity between patient samples, that resulted in no
252 significant correlation between the time post vaccination and infectious viral shedding
253 **(Supplementary figure S4).**

254 **In previously vaccinated subjects infection with Omicron VOC results in similar infectious viral loads**
255 **like Delta**

256 Upon emergence of new VOC Omicron, we analysed the infectious viral shedding in vaccinated
257 patients infected with this variant. We compared RNA and infectious viral loads in nasopharyngeal
258 swab samples of 18 Omicron and 17 Delta infected patients. Vaccine breakthrough infection with
259 Omicron or Delta variant resulted in comparable SARS-CoV-2 genome copies (p= 0·3345). Modestly
260 lower infectious viral titres were detected in Omicron infected patients in comparison to Delta
261 infected patients, however this difference was not statistically significant (0·69 log, p= 0.1033) (Figure
262 5). Same moderate but non-significant reduction of infectious viral titres was observed for Omicron
263 samples when matching patients for age, sex and dpos (**Supplementary figure 3C**).

264

265 # Discussion

266 In this study we analysed virus shedding in COVID-19 patients infected with pre-VOC, Delta VOC and
267 Omicron VOC SARS-CoV-2 and evaluated the impact of vaccination on viral load in the URT during the
268 first 5 dpos. To our knowledge, this is the first study which quantified infectious viral loads in patients
269 infected with different SARS-CoV-2 variants and vaccination breakthrough cases. We could
270 demonstrate a higher infectious viral load in unvaccinated Delta-infected compared to pre-VOC-
271 infected patients and showed a significant reduction of infectious viral loads in vaccinated patients.
272 Furthermore, we found no difference in infectious viral load between Delta and Omicron
273 breakthrough cases.

274 Determining the magnitude and timing of infectiousness of COVID-19 patients is a key requirement to
275 make informed public health decisions on the duration of isolation of patients and on the need to
276 quarantine contacts. Infectiousness is strongly influenced by viral load in the URT of infected patients
277 (4). However, in most studies viral load is measured as RNA genome copies and not actual infectious
278 virus. In this study we could show that detection of RNA genome copies in URT swab samples is only
279 poorly correlated with infectious virus shedding. This is in line with several other studies that found
280 that RNA is a poor indicator of infectiousness especially in the presence of neutralising antibodies (12,
281 37).In addition, in a golden hamster animal model it was demonstrated that only infectious virus but
282 not RNA is a good proxy for onward transmission (10).

283 Virus isolation success in cell culture has been widely used as a proxy for infectiousness (6, 12, 33, 40).
284 Several studies have shown that virus isolation success significantly drops when RNA viral loads are
285 below 6 log10 copies per mL in viral transport medium, or collected later than 8 days post symptom
286 onset. Of note, with only a qualitative result on either successful isolation or not, overall virus isolation
287 success cannot distinguish between high and low infectious viral loads in a patient sample, a key
288 determinant of the size of the transmitted inoculum. Differences in infectious virus load however can
289 have an impact on transmission probability. Therefore, we decided to use a focus forming assay
290 instead that can reliably quantify infectious viral particles from original patient specimens. Focus
291 forming assays have long been used as a standard to quantify excretion of virus in animal infection
292 models for respiratory viruses such as SARS-CoV-2 and influenza virus and are therefore considered
293 one of the best available proxies for infectiousness (41, 42).

294 Within the first 5 dpos, we found higher RNA genome copies in swabs of unvaccinated patients
295 infected with pre-VOC compared to Delta VOC, but infectious viral titres were higher for Delta VOC.
296 These results are in disagreement with other studies that analysed only nucleic acid detection and
297 found 3-10-fold higher RNA genome copies in Delta VOC infected patients compared to pre-VOC (18,
298 43). However, these studies did not control for days post symptom onset, age or sex. Other studies
299 found either no difference in RNA genome copies between Delta and pre-VOC swabs (44) or more
300 than 1000-fold higher viral load for Delta VOC (45, 46), documenting the difficulty of comparing RNA
301 viral loads of virus variants during different phases of the pandemic, especially when not taking
302 additional information such as days post symptom onset into account. Conversely, in agreement with
303 our results, a higher virus isolation success rate was observed for Delta compared to pre-VOC SARS-
304 CoV-2 or Alpha VOC (47, 48).

305 Vaccines have been shown to tremendously reduce symptomatic SARS-CoV-2 infections. However,
306 the impact of vaccination on the infectiousness of breakthrough cases is less clear. We could show
307 that infectious viral load but not RNA genome copies are reduced in vaccinated Delta VOC patients
308 during the first 5 days post symptom onset. In this time period approximately 50% of transmissions
309 occur for pre-VOC SARS-CoV-2 strains (5), indicating that a reduction of viral load could considerably

310 contribute to a decreased secondary attack rate. Similar observations were made in other studies that
311 found no difference in RNA genome copies between vaccinated and unvaccinated early after symptom
312 onset (29, 30), but detected a lower probability of virus isolation success (30). Conversely, another
313 study detected up to 10-fold reduced RNA genome copies in vaccinated patients but only during the
314 first 60 days after complete vaccination (27). Similarly, two more studies reported decreased RNA
315 genome copies for vaccine breakthrough infection with pre-VOC and Alpha VOC SARS-CoV-2 (26), but
316 the effect vanished around 6 months post vaccination when Delta VOC was present (28). Of note, we
317 were still able to detect infectious viral particles in 53·8%% of vaccinated subjects at 5 dpos, indicating
318 that it might be beneficial is not shortened to 5 days as recently recommended by the CDC(49)..
319 Whether lower infectious viral load translates into lower secondary attack rate remains controversial
320 and depends on other influencing factors, i.e. environmental stability of virus particles. Several studies
321 did find a correlation between higher viral load and increased secondary attack rate, with viral load of
322 the index case being the leading driver of transmission (3, 4). In agreement with these finding,
323 epidemiological studies also showed reduced transmission rates when index cases were vaccinated,
324 but the effect size depends on the prevalent variant, the vaccine used and the time elapsed since
325 complete vaccination (22). In contrast, another study found that the vaccination status of the index
326 case did not influence the secondary attack rate (25). While VL is a key element of transmission, the
327 process of human-to-human transmission is complex and other factors, such as recommended
328 protection measures in a certain country at a certain time, overall incidence, perceived risks and the
329 context of contacts (household *vs* community transmission) can influence outcomes in the studies
330 reported.

331 To date, few data exist on viral load in vaccine breakthrough infections caused by the Omicron VOC
332 due to the recent emergence in late November 2021. Reduced neutralization of Omicron by infection-
333 and vaccine-derived antibodies was reported *in vitro* and epidemiological studies show an increased
334 risk of (re-)infection with Omicron in vaccinated and previously infected individuals (50, 51).
335 Furthermore, very high transmissibility of Omicron breakthrough infections was observed, with high
336 secondary attack rates even among vaccinated individuals (52). Higher RNA viral loads as described in
337 some studies were discussed as one potential contributing factor for the emergence of Alpha and
338 Delta VOC, although for Delta we could only confirm this for infectious viral load in our data. The
339 contribution of VL to the high transmissibility of Omicron is not known so far, neither is the mechanism
340 behind higher transmissibility of Omicron. First in vitro data hint towards alternative entry
341 mechanisms as well as early replication peak in cell culture (53), but no clinical data for this
342 phenomenon exist so far. Our findings indicate that with comparable RNA viral load as well as
343 comparable infectious virus shedding, the higher transmissibility in Omicron doesn't seem to be
344 related to the shedding of an increased number of infectious viral particles in vaccinated individuals.

345 Our study has several limitations. We included only samples with Ct values below 27, collected during
346 the first 5 dpos but not afterwards. Therefore, absolute numbers on RNA copies are biased towards
347 higher viral loads as patients with low viral load were not included here. However, patients with low
348 viral load have likely little relevance in terms of transmission and other factors, such as poor swab
349 quality can be a confounding factor leading to low viral loads. Furthermore, our focus was on
350 infectious virus shedding and it has been shown that SARS-CoV-2 culture is unlikely to be successfully
351 from samples with higher Ct values (35) and that the vast majority of secondary transmission occurs
352 before 5 dpos although this needs to be formally assessed in Omicron cases (5). Due to its recent
353 emergence, we did not yet have access to samples from Omicron infected unvaccinated individuals.
354 Last, we also would like to emphasize that almost all patients in this study were vaccinated with mRNA
355 vaccines that induce high titres of neutralizing antibodies in the blood but relatively low mucosal

antibodies. Therefore, our results cannot be generalized to other vaccines, i.e. those that are used mainly in low- and middle-income countries.

In conclusion, this study provides strong evidence for higher infectiousness of the Delta VOC as well as a significantly lower infectiousness and a faster clearance of infectious virus in vaccinated individuals. In addition, we could show that Omicron has similar infectious viral loads than Delta VOC. Furthermore, we show a more detailed picture of viral load assessment in addition to overall virus isolation success, and that quantifying viral loads can give better insights into viral shedding kinetics in acute SARS-CoV-2 infection.

Funding

This work was supported by the Swiss National Science Foundation 196644, 196383, NRP (National Research Program) 78 Covid-19 Grant 198412, the Fondation Ancrage Bienfaisance du Groupe Pictet and the Fondation Privée des Hôpitaux Universitaires de Genève.

Acknowledgments

We thank all patients for their willingness to participate in our research. We thank the staff of the laboratory of virology from the University Hospitals of Geneva for their support.

373 **Table**

	Pre-VOC SARS-CoV-2	SARS-CoV-2 Delta VOC	Vaccine breakthrough infections (Delta VOC)	Vaccine breakthrough infections (Omicron VOC)
Number	118	127	121*	18
Sampling dates	April 7 - September 9 2020	June 26 –August 29 2021	July 8 -December 4 2021	December 14 – December 17
Age				
Median (range)	36 (17-82)	37 (16-83)	40 (16-83)	35 (14-58)
<25	22 (18·6%)	19 (14·9 %)	14 (11·6%)	
25-35	37 (31·4%)	38 (29·9%)	36 (29·8%)	
35-50	30 (25·4%)	41 (32·3%)	44 (36·3%)	
50-65	23 (19·5%)	25 (19·7%)	24 (19·8%)	
>65	6 (5·1%)	4 (3·1%)	3 (2·5%)	
Sex				
Female	50 (42·4%)	65 (51·2%)	62 (51·2%)	9 (50 %)
Male	68 (57·6%)	62 (48·8%)	59 (48·8%)	9 (50 %)
RT-PCR result, CT (E-gene target, Cobas 6800, Roche)	13·9-26·6	13·8-26·3	16·3-26·1	17.2-25.9
Interval vaccination to infection, days, mean (IQR)	na	na	79·5 (IQR 40·5-139 days)	136 (IQR 85-176)
Vaccine				
BNT162b2	na	na	43	8
mRNA-1273	na	na	73	8
CoviVac	na	na	1	-
Vaccine unknown	na	na	4	2

374 **Table 1.** Patient characteristics of the specimens used in this study. RT-PCR, reverse transcription
375 polymerase chain reaction, CT, cycle threshold, IQR, interquartile range, na, not applicable. *Of the all
376 121 vaccine breakthrough samples, 104 were titrated in parallel with Delta VOC infection and 17 in
377 parallel with Omicron vaccine break through infections.

378 **Figures**



379

380 **Figure 1. Quantitative infectious viral loads versus overall virus isolation success** (**A**) Vero E6 cells
381 were inoculated with 10-fold serial dilutions of nasopharyngeal swabs collected from SARS-CoV-2
382 infected individuals. Plates were fixed 27 h post-infection and following the staining with SARS-CoV-2
383 specific antibodies, the number of focus forming units (FFU)/ml was calculated for each sample.
384 Error bars indicate mean±SD. p-values were calculated with the one-way ANOVA. ***: p<0·002;
385 ****p<0·0001. (**B**) The total number of positive and negative samples defined by titration and virus
386 isolation for each patient group. Cohens kappa agreement is shown.



Figure 2. Relationship between RNA viral loads and infectious viral titers. Linear regression analysis of infectious viral titers in FFU/ml and the corresponding RNA viral loads in nasopharyngeal swabs from the unvaccinated patients infected with pre-VOC (**A**), and Delta SARS-CoV-2(**B**) as well as Delta vaccination breakthroughs (**C**).



Figure 3. RNA viral load and infectious viral titers for unvaccinated individuals infected with pre-VOC SARS-CoV-2 vs. Delta (A) Genome copies (left panel) and infectious virus (right panel) for pre-VOC and Delta unvaccinated patients. Error bars indicate mean±SD. The t-test was used to determined differences of means. *p=0·0373; **** p<0·0001. Genome copies **(B)** and infectious viral loads **(C)** measured for pre-VOC and Delta VOC infected patients at different dpos. The solid lines represent the fitted curve calculated using (locally estimated scatterplot smoothing) LOESS method.



Figure 4. RNA viral load and infectious viral titers for unvaccinated vs. vaccinated individuals infected Delta (A) Genome copies (left panel) and infectious virus (right panel) for vaccinated and unvaccinated Delta infected patients. Error bars indicate mean±SD. The t-test was used to determined differences of means. ***p=0·0005; ****p<0·0001. Genome copies **(B)** and infectious viral loads (C) measured for vaccinated and unvaccinated Delta infected patients at different dpos. The solid lines represent the fitted curve calculated using (locally estimated scatterplot smoothing) LOESS method.



408

409 **Figure 5. SARS-CoV-2 infectious viral loads in vaccine break through infections with Omicron or**
410 **Delta. (A)** Genome copies (left panel) and infectious virus (right panel) for vaccinated patients
411 infected with Delta or Omicron VOC Infectious viral loads (were determined by focus-forming assay
412 on Vero-TMPRSS cells. Significance was determined by t-test. ns: nonsignificant

413

414

415 # References

416 1. Weekly epidemiological update on COVID-19 - 6 January 2022. World Health Organization;
417 2022.
418 2. Kawasuji H, Takegoshi Y, Kaneda M, Ueno A, Miyajima Y, Kawago K, et al. Transmissibility of
419 COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLoS
420 One. 2020;15(12):e0243597.
421 3. Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, et al. Quantifying
422 the relationship between SARS-CoV-2 viral load and infectiousness. Elife. 2021;10.
423 4. Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monné M, et al.
424 Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect
425 Dis. 2021;21(5):629-36.
426 5. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and
427 transmissibility of COVID-19. Nat Med. 2020;26(5):672-5.
428 6. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
429 assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9.
430 7. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting Infectious Severe
431 Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis.
432 2020;71(10):2663-6.
433 8. Glans H, Gredmark-Russ S, Olausson M, Falck-Jones S, Varnaite R, Christ W, et al. Shedding
434 of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody
435 responses. BMC Infectious Diseases. 2021;21(1):494.
436 9. Vetter P, Eberhardt CS, Meyer B, Martinez Murillo PA, Torriani G, Pigny F, et al. Daily Viral
437 Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
438 mSphere. 2020;5(6).
439 10. Sia SF, Yan L-M, Chin AWH, Fung K, Choy K-T, Wong AYL, et al. Pathogenesis and
440 transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834-8.
441 11. Munker D, Osterman A, Stubbe H, Muenchhoff M, Veit T, Weinberger T, et al. Dynamics of
442 SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19
443 patients. Eur Respir J. 2021;58(1).
444 12. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al.
445 Duration and key determinants of infectious virus shedding in hospitalized patients with
446 coronavirus disease-2019 (COVID-19). Nature Communications. 2021;12(1):267.
447 13. Despres HW, Mills MG, Shirley DJ, Schmidt MM, Huang M-L, Jerome KR, et al. Quantitative
448 measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals
449 higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon
450 variants. medRxiv. 2021:2021.09.07.21263229.
451 14. Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-
452 pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update. European
453 Centre for Disease Prevention and Control; 2021.
454 15. Xia S, Wen Z, Wang L, Lan Q, Jiao F, Tai L, et al. Structure-based evidence for the enhanced
455 transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). Cell Discov.
456 2021;7(1):109.
457 16. Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Antibody evasion by the
458 P.1 strain of SARS-CoV-2. Cell. 2021;184(11):2939-54.e9.
459 17. Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al.
460 Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021;373(6551).
461 18. Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, et al. The Delta
462 SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in
463 nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021;83(4):e1-
464 e3.

465 19. Imai K, Ikeno R, Tanaka H, Takada N. SARS-CoV-2 Delta variant saliva viral load is 15-fold
466 higher than wild-type strains. medRxiv. 2021:2021.11.29.21266980.
467 20. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A Single-Dose
468 Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2.
469 Cell. 2020;183(1):169-84.e13.
470 21. Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host
471 transmission by SARS-CoV-2 vaccines. Lancet Infect Dis. 2021.
472 22. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on
473 Household Transmission of SARS-CoV-2 in England. N Engl J Med. 2021;385(8):759-60.
474 23. Layan M, Gilboa M, Gonen T, Goldenfeld M, Meltzer L, Andronico A, et al. Impact of
475 BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an
476 observational study. medRxiv. 2021:2021.07.12.21260377.
477 24. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of SARS-
478 CoV-2 vaccination on Alpha & Delta variant transmission. medRxiv.
479 2021:2021.09.28.21264260.
480 25. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community
481 transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated
482 and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet
483 Infect Dis. 2021.
484 26. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-
485 19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an
486 exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351-62.
487 27. Levine-Tiefenbrun M, Yelin I, Alapi H, Katz R, Herzel E, Kuint J, et al. Viral loads of Delta-
488 variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
489 Nature Medicine. 2021;27(12):2108-10.
490 28. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Effect of Delta
491 variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the
492 UK. Nature Medicine. 2021;27(12):2127-35.
493 29. Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte JM, Mak TM, et al. Virological and serological
494 kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort
495 study. Clin Microbiol Infect. 2021.
496 30. Shamier MC, Tostmann A, Bogers S, de Wilde J, IJpelaar J, van der Kleij WA, et al. Virological
497 characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers.
498 medRxiv. 2021:2021.08.20.21262158.
499 31. Badu K, Oyebola K, Zahouli JZB, Fagbamigbe AF, de Souza DK, Dukhi N, et al. SARS-CoV-2
500 Viral Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge
501 Guidelines. Front Med (Lausanne). 2021;8:648660.
502 32. Sabine Yerly LK, Manuel Schibler, Isabella Eckerle. Protocol for specific RT-PCRs for marker
503 regions of the Spike indicative of the Omicron variant (B.1.1.529). Geneva, Switzerland:
504 Centre for Emerging Viral Diseases, Geneva University Hospitals; December 2,2021.
505 33. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019
506 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3).
507 34. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–
508 April 30, 2021. 2021 May 28, 2021.
509 35. Essaidi-Laziosi M, Perez Rodriguez FJ, Hulo N, Jacquerioz F, Kaiser L, Eckerle I. Estimating
510 clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells. Lancet
511 Microbe. 2021;2(11):e571.
512 36. Chen PZ, Bobrovitz N, Premji ZA, Koopmans M, Fisman DN, Gu FX. SARS-CoV-2 shedding
513 dynamics across the respiratory tract, sex, and disease severity for adult and pediatric
514 COVID-19. Elife. 2021;10.

515 37. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral Cultures for Coronavirus Disease 2019
516 Infectivity Assessment: A Systematic Review. Clin Infect Dis. 2021;73(11):e3884-e99.
517 38. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in
518 immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315-
519 20.
520 39. Owusu D, Pomeroy MA, Lewis NM, Wadhwa A, Yousaf AR, Whitaker B, et al. Persistent SARS-
521 CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With
522 COVID-19. J Infect Dis. 2021;224(8):1362-71.
523 40. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in
524 Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis.
525 2020;26(10):2494-7.
526 41. Wong L-YR, Li K, Sun J, Zhuang Z, Zhao J, McCray PB, et al. Sensitization of Non-permissive
527 Laboratory Mice to SARS-CoV-2 with a Replication-Deficient Adenovirus Expressing Human
528 ACE2. STAR Protocols. 2020;1(3):100169.
529 42. Blazejewska P, Koscinski L, Viegas N, Anhlan D, Ludwig S, Schughart K. Pathogenicity of
530 different PR8 influenza A virus variants in mice is determined by both viral and host factors.
531 Virology. 2011;412(1):36-45.
532 43. Christian von Wintersdorff JD, Lieke van Alphen, Petra Wolffs, Brian van der Veer, Christian
533 Hoebe, Paul Savelkoul. Infections caused by the Delta variant (B.1.617.2) of SARS-CoV-2 are
534 associated with increased viral loads compared to infections with the Alpha variant (B.1.1.7)
535 or non-Variants of Concern2021.
536 44. Tani-Sassa C, Iwasaki Y, Ichimura N, Nagano K, Takatsuki Y, Yuasa S, et al. Viral loads and
537 profile of the patients infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo. J Med
538 Virol. 2021.
539 45. Siedner MJ, Boucau J, Gilbert RF, Uddin R, Luu J, Haneuse S, et al. Duration of viral shedding
540 and culture positivity with post-vaccination SARS-CoV-2 delta variant infections. JCI Insight.
541 2021.
542 46. Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, et al. Transmission, viral kinetics and clinical
543 characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China.
544 EClinicalMedicine. 2021;40:101129.
545 47. Boschi C, Aherfi S, Houhamdi L, Colson P, Raoult D, Scola B. Isolation of 4000 SARS-CoV-2
546 shows that contagiousness is associated with viral load, not vaccine or symptomatic status.
547 Emerg Microbes Infect. 2021;10(1):2276-8.
548 48. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston DC, Li M, et al. Infection with the
549 SARS-CoV-2 Delta Variant is Associated with Higher Recovery of Infectious Virus Compared
550 to the Alpha Variant in both Unvaccinated and Vaccinated Individuals. Clin Infect Dis. 2021.
551 49. Prevention CfDCa. CDC Updates and Shortens Recommended Isolation and Quarantine
552 Period for General Population. December 27, 2021.
553 50. Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B, et al.
554 Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and
555 previously infected individuals, the Netherlands, 22 November to 19 December 2021.
556 medRxiv. 2021:2021.12.20.21268121.
557 51. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al.
558 Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant
559 in South Africa. medRxiv. 2021:2021.11.11.21266068.
560 52. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the
561 SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill.
562 2021;26(50).
563 53. Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The SARS-CoV-2
564 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and
565 efficiently uses the endosomal route of entry. bioRxiv. 2022:2021.12.31.474653.

Supplementary figures



Supplementary figure S1. Linear regression analysis of SARS-CoV-2 titers in FFU/ml and the corresponding age of the patient.



Supplementary figure S2. Comparison of infectious viral shedding measured in female and male patients. Error bars indicate mean±SD. The t-test was used to determine differences of means. ns= nonsignificant.



Supplementary figure S3. SARS-CoV-2 infectious viral loads detected in unvaccinated patients infected with pre-VOC or Delta (A), unvaccinated and vaccinated patients infected with Delta (B), vaccinated patients infected with Delta or Omicron (C) matched by age, sex, and dpos. Error bars indicate mean±SD.. **p=0·001170; ****p<0·0001, ns=nonsignificant.



Supplementary Figure S4. Linear regression analysis of infectious viral shedding and time since the completion of vaccination in Delta infected patients.